Blog

TOWARDS Study: Xenograft Engraftment Predicts Poor Survival in TNBC

Naoto T. Ueno/LinkedIn

Aug 1, 2024, 06:24

TOWARDS Study: Xenograft Engraftment Predicts Poor Survival in TNBC

Naoto T. Ueno, Director at University of Hawaii Cancer Center, shared a post on X, about a recent paper published in JCO Precision Oncology:

TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer.

Authors: Christos Vaklavas, Cindy B. Matsen, Zhengtao Chu, Kenneth M. Boucher, Sandra D. Scherer, Satya Pathi, Anna Beck, Kirstyn E. Brownson, Saundra S. Buys, Namita Chittoria, Elyse D’Astous, H. Evin Gulbahce, N. Lynn Henry, Stephen Kimani, Jane Porretta, Regina Rosenthal, John Ward, Mei Wei, Bryan E. Welm, Alana L. Welm.

Naoto T. Ueno

”A fascinating result is that engraftment to develop PDX predicts the response to systemic treatment in patients with triple-negative breast cancer. This is an article by a great cancer biologist, Alana Welm.”

Source: Naoto T. Ueno/X

Alana Welm Anna Beck Breast Cancer Bryan E. Welm cancer cancer treatment Christos Vaklavas Cindy B. Matsen Elyse D'Astous H. Evin Gulbahce Jane Porretta JCO Precision Oncology John Ward Kenneth M. Boucher Kirstyn E. Brownson Mei Wei N. Lynn Henry Namita Chittoria Naoto T Ueno OncoDaily Oncology Regina Rosenthal Sandra D. Scherer Satya Pathi Saundra S. Buys Stephen Kimani University of Hawaii Cancer Center Zhengtao Chu

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage